Superworth

Seres Therapeutics EPS MCRB

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
−$2.33
Latest quarter, Q2 FY26
$0.47
Fiscal year 2025
$0.76

Seres Therapeutics' earnings per share was −$2.33 over the twelve months to Jun 30, 2026, down 121% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.47.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$0.76n/a
FY2024−$0.03n/a
FY2023−$18.00n/a
FY2022−$47.00n/a
FY2021−$14.80n/a
FY2020−$22.40n/a
FY2019−$26.60n/a
FY2018−$48.60n/a
FY2017−$44.20n/a
FY2016−$45.80n/a
FY2015−$75.60n/a
FY2014−$55.40n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.47n/a−$2.33
Q1 FY26−$2.08−155%−$5.07
Q4 FY25−$1.66n/a$0.76
Q3 FY25$0.94−92%$0.59
Q2 FY25−$2.27n/a$11.28
Q1 FY25$3.75n/a$9.21
Q4 FY24−$1.83n/a−$0.03
Q3 FY24$11.63n/a−$4.60
Q2 FY24−$4.34−160%−$23.63
Q1 FY24−$5.49n/a−$12.09
Q4 FY23−$6.40n/a−$18.00
Q3 FY23−$7.40n/a−$22.60

Against its peers

Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
MCRBSeres Therapeutics−$2.33−121% a year
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Seres Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.